Skye Bioscience (NASDAQ:SKYE – Get Free Report)‘s stock had its “overweight” rating reaffirmed by investment analysts at Cantor Fitzgerald in a research note issued on Tuesday, Benzinga reports. They currently have a $14.00 price objective on the stock. Cantor Fitzgerald’s target price indicates a potential upside of 104.08% from the stock’s previous close.
Separately, Craig Hallum initiated coverage on shares of Skye Bioscience in a research note on Tuesday, July 9th. They issued a “buy” rating and a $18.00 target price on the stock.
Check Out Our Latest Research Report on Skye Bioscience
Skye Bioscience Stock Performance
Skye Bioscience (NASDAQ:SKYE – Get Free Report) last posted its earnings results on Friday, August 9th. The company reported ($0.20) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.20). As a group, equities research analysts anticipate that Skye Bioscience will post -0.95 EPS for the current year.
Institutional Trading of Skye Bioscience
Several large investors have recently bought and sold shares of the company. Cubist Systematic Strategies LLC purchased a new position in shares of Skye Bioscience in the second quarter valued at $30,000. Point72 DIFC Ltd acquired a new position in Skye Bioscience in the 2nd quarter worth $48,000. Rhumbline Advisers acquired a new position in Skye Bioscience in the 2nd quarter worth $158,000. AdvisorShares Investments LLC purchased a new position in Skye Bioscience in the 2nd quarter valued at about $210,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Skye Bioscience during the second quarter valued at about $222,000. Institutional investors and hedge funds own 21.09% of the company’s stock.
About Skye Bioscience
Skye Bioscience, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy.
Read More
- Five stocks we like better than Skye Bioscience
- Market Cap Calculator: How to Calculate Market Cap
- BJ’s Stock Slides After Q2 Beat: A Buy-the-Dip Opportunity?
- What is Put Option Volume?
- Oil Prices Are Breaking Out: Top 3 Stocks to Watch Right Now
- Basic Materials Stocks Investing
- Immersion Stock Surges as It Monetizes Haptic Technology Patents
Receive News & Ratings for Skye Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Skye Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.